Search
for

    Learn

    5 / 801 results

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community Regrowth 21 months, fin, 41 Male

      in Progress Pictures  592 upvotes 2 years ago
      A user shared their 21-month hair regrowth journey using oral Finasteride 1mg daily and Minoxidil 5% topical applications. Despite initial discouragement due to slow progress, they saw significant improvement, reducing the need for a hair transplant to minor fill-ins at the front hairline.

      community If you are a young guy worrying about hairloss

      in Shaved/buzzed  169 upvotes 2 years ago
      A 26-year-old man embraced baldness, gaining confidence and personal growth, and encourages self-acceptance. Others discussed hair loss treatments like Minoxidil and finasteride, but he did not use them.

      community DUPA, Non Responders and Connective Tissue Disorders

      in Research/Science  9 upvotes 10 months ago
      A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

      community DUPA - Impossible to cure, so giving up

      in Update  3 upvotes 6 months ago
      The user diagnosed with DUPA tried treatments like dutasteride, finasteride, RU58841, and minoxidil without success and is considering a hair system. They hope for a future cure, possibly with PP405, and others suggest options like scalp biopsy and SMP.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.